Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (1259) clinical trials

Testing The Addition of a New Anti-cancer Drug Venetoclax to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated Older Patients With Chronic Lymphocytic Leukemia

PRIMARY OBJECTIVE: I. To compare the progression-free survival (PFS) between control treatment and experimental treatment strategies: ibrutinib/obinutuzumab (IO) with ibrutinib maintenance (IM) versus ibrutinib/venetoclax/obinutuzumab (IVO) regardless of IM or observation. SECONDARY OBJECTIVES: I. To compare bone marrow (BM) minimal residual disease (MRD)- complete response (CR) rates and depth of response ...

Phase

2.73 miles

Learn More »

Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

PRIMARY OBJECTIVES: I. To assess whether ALK kinase domain mutations (G1202/C1156Y/I1171/L1196/ V1180/ F1174/compound mutation) associated with drug resistance are prognostic for objective response to subsequent ALK inhibitor therapy. II. To assess whether subsequent pemetrexed based chemotherapy improves objective response comparing to ALK inhibitor therapy for no ALK mutation patients. III. ...

Phase

2.73 miles

Learn More »

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

PRIMARY OBJECTIVES: I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) associated with rucaparib in patients with genomic LOH high and/or deleterious BRCA1/2 mutations within: Cohort 1: Patients with squamous cell histology or mixed histology with a squamous component; Cohort 2: Patients with non-squamous histology ...

Phase

2.73 miles

Learn More »

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Phase 3b multinational, multicenter, double-blind, placebo-controlled, randomized withdrawal, parallel group study that includes screening and 12 weeks Run-in Phase (where RAASi medications, including mineralocorticoid receptor antagonist (MRA) will be optimized for all subjects) and a randomized withdrawal Blinded Treatment Phase. Subjects with heart failure with reduced ejection fraction (HFrEF) who ...

Phase

2.73 miles

Learn More »

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

PRIMARY OBJECTIVES: I. To compare overall survival between patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer randomized to ramucirumab and MK-3475 (pembrolizumab) versus standard of care (SoC). SECONDARY OBJECTIVES: I. To compare response rates between the arms, including complete response (CR) ...

Phase

2.73 miles

Learn More »

Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To compare progression free survival (PFS) for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation +/- atezolizumab. (Phase II) II. To compare overall survival (OS) for patients with LS-SCLC treated with chemoradiation +/- atezolizumab. (Phase III) SECONDARY OBJECTIVES: I. To compare progression free ...

Phase

2.73 miles

Learn More »

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Primary Objective of the Master Protocol (LUNGMAP) The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol. Secondary Objectives Screening Success Rate Objective To evaluate the screen success rate defined as ...

Phase

2.73 miles

Learn More »

Youth Opioid Recovery Support: Improving Care Systems

Opioid addiction, also referred to as opioid use disorder, among young people is a growing health concern for patients and their families. Overdose deaths related to opioids have been steadily increasing in number and are at an all-time high. Opioid addiction has serious consequences such as getting HIV, legal problems, ...

Phase N/A

2.73 miles

Learn More »

A Study of Psilocybin for Major Depressive Disorder (MDD)

Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the United States will experience an episode of major depression in his or her lifetime, and it is estimated that major depression will rank second after cardiac disease as ...

Phase

2.73 miles

Learn More »

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.

Phase

2.73 miles

Learn More »